Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX plus bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis

被引：0
|
作者：
Peria, F. M. [1 ]
Ungari, A. Q. [1 ]
Dos Santos, F. N. [1 ]
Lins-Almeida, T. [2 ]
Nunes, A. A. [1 ]
机构：
[1] Univ Sao Paulo, Fac Med, HCRP Hosp Clin, Internal Med Div Oncol, Ribeirao Preto, Brazil
[2] Univ Sao Paulo, Fac Med, HCRP Hosp Clin, Internal Med, Ribeirao Preto, Brazil
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw387.29
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1393p
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of capecitabine plus oxaliplatin (XELOX)A new first-line option in metastatic colorectal cancer
    Thomas Makatsoris
    Haralabos P. Kalofonos
    Gerasimos Aravantinos
    Christos Papadimitriou
    Efstathios Kastritis
    Sotirios K. Rigatos
    Nikolaos Xiros
    Theodore Petsas
    Theofanis Economopoulos
    Athanassios K. Sakadamis
    George Fountzilas
    [J]. International Journal of Gastrointestinal Cancer, 2005, 35 (2): : 103 - 109
  • [32] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Yu Hong Li
    Hui Yan Luo
    Feng Hua Wang
    Zhi Qiang Wang
    Miao Zhen Qiu
    Yan Xia Shi
    Xiao Juan Xiang
    Xiao Qing Chen
    You Jian He
    Rui Hua Xu
    [J]. Journal of Cancer Research and Clinical Oncology, 2010, 136 : 503 - 510
  • [33] Cost-effectiveness of capecitabine in combination with oxaliplatin (XELOX) compared with FOLFOX for the treatment of metastatic colorectal cancer: A Canadian evaluation
    Belovich, D.
    Hux, M.
    Douglas, P.
    Maroun, J. A.
    Sommer, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.
    Xu, Rui-Hua
    Wang, Feng
    Peng, Junjie
    Liang, Xinjun
    Cheng, Ying
    Deng, Yanhong
    Chen, Kehe
    Zhang, Mingjun
    Zhang, Jingdong
    Wang, Wei
    Cao, Bangwei
    Jin, Yongdong
    Sun, Meili
    Lin, Yuan
    Luo, Su-Xia
    Li, Zhen
    Yang, Liu
    Wang, Qingyu
    Li, Jing
    Zhu, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 124 - 124
  • [35] PRELIMINARY EFFICACY, SAFETY AND OPERABILITY OF BEVACIZUMAB(BV) PLUS CAPECITABINE PLUS OXALIPLATIN (XELOX) AS FIRST-LINE THERAPY IN JAPANESE PATIENTS (PTS) WITH INITIALLY UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
    Yamaguchi, K.
    Boku, N.
    Kato, K.
    Komatsu, Y.
    Muro, K.
    Hamamoto, Y.
    Sato, A.
    Koizumi, W.
    Mizunuma, N.
    Takiuchi, H.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [36] Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study
    Kezban Nur Pilancı
    Sezer Saglam
    Alper Okyar
    Serap Yucel
    Zeliha Pala-Kara
    Cetin Ordu
    Esat Namal
    Rumeysa Ciftci
    Ulkuhan Iner-Koksal
    Esra Kaytan-Saglam
    [J]. Cancer Chemotherapy and Pharmacology, 2016, 78 : 143 - 150
  • [37] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
    Cassinello, J.
    Alvarez, J. V.
    Garcia-Lopez, M. J.
    Pujol, E.
    Colmenarejo, A.
    De Segovia, F.
    Marcos, F.
    Filipovich, E.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
  • [38] Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer
    Grande, Carlos
    Quintero, Guillermo
    Candamio, Sonia
    Paris Bouzas, Lorena
    Jose Villanueva, Maria
    Campos, Begona
    Gallardo, Elena
    Alvarez, Elena
    Casal, Joaquin
    Ramon Mel, Jose
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (02) : 114 - 121
  • [39] Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study
    Pilanci, Kezban Nur
    Saglam, Sezer
    Okyar, Alper
    Yucel, Serap
    Pala-Kara, Zeliha
    Ordu, Cetin
    Namal, Esat
    Ciftci, Rumeysa
    Iner-Koksal, Ulkuhan
    Kaytan-Saglam, Esra
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (01) : 143 - 150
  • [40] Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/ irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
    Scheithauer, W.
    Prager, G.
    Greil, R.
    Mlineritsch, B.
    Schaberl-Moser, R.
    Gerger, A.
    Laengle, F.
    Viragos-Toth, I.
    Andel, J.
    Pichler, A.
    Pecherstorfer, M.
    Kretschmer, A.
    Seebacher, A.
    Jagdt, B.
    Eisterer, W.
    Krippl, P.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
12345